BioAlliance Pharma Announces: Grant of Orphan Designation for clonidine Lauriadâ„¢ in Europe  
11/3/2011 8:44:19 AM

PARIS--(BUSINESS WIRE)--Regulatory News:

BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced that clonidine Lauriadâ„¢ has been granted orphan designation by the European Commission in the prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer.